CALX vs. MNPR

In the year-to-date period, CALX achieves a 32.61% return, which is significantly lower than MNPR's 44.23% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Calix, Inc. (CALX) and Monopar Therapeutics Inc. (MNPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CALX Sharpe Ratio is 0.71, which is lower than the MNPR Sharpe Ratio of 1.53. The chart below compares the historical Sharpe Ratios of CALX and MNPR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CALX nor MNPR has paid dividends to shareholders.

The maximum CALX drawdown since its inception was -80.95%, smaller than the maximum MNPR drawdown of -98.93%. Use the drawdown chart below to compare losses from any high point for CALX and MNPR.

The current volatility for Calix, Inc. (CALX) is 4.29%, while Monopar Therapeutics Inc. (MNPR) has a volatility of 26.05%. This indicates that CALX experiences smaller price fluctuations and is considered to be less risky than MNPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Calix, Inc. and Monopar Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.